Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome

Bondi, Johan; Husdal, A; Bukholm, Geir; Nesland, Jahn M.; Bakka, Arne; Bukholm, Ida Rashida Khan

doi:10.1136/jcp.2004.020347

Cited by 66 publications

(81 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The findings of Wang et al support the theory of overexpression of cyclin E in CRC without a significant correlation with clinical and pathological characteristics (33). Bondi et al did not identify a significant correlation between cyclin E expression and gene amplification in primary colon adenocarcinomas and clinical outcome (34). Cyclin E was found to be higher in rectal cancer compared with colon cancer in a study from Norway (35).…”

Section: A B Csupporting

confidence: 70%

Expression of cyclin E in stage III colorectal carcinoma

et al. 2012

View full text Add to dashboard Cite

Abstract. Carcinogenesis is characterized by an abnormal regulation of the cell cycle. Regulators of the cell cycle such as cyclin E play an important role in neoplasia and may be correlated with prognosis. The clinical significance of the expression of cyclin E in stage III colorectal carcinoma has not yet been investigated. The expression of cyclin E was evaluated in 49 patients. Using a multivariate analysis, the expression of cyclin E in the tumor at diagnosis was compared with various clinicopathological variables, including age, gender, tumor site, tumor size, tumor differentiation and lymph node involvement. There were more node-positive cases in the cyclin E-negative group than in the cyclin E-positive group (P=0.003). However, there was no correlation between the degree of cyclin E expression and the clinical data. In conclusion, our data suggest that overexpression of cyclin E does not predict the clinical outcome in colorectal cancer stage III. Negative cyclin E staining may be associated with lymph node involvement.

show abstract

Section: A B Csupporting

confidence: 70%

Expression of cyclin E in stage III colorectal carcinoma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The findings of Bondi et al are congruent with the report of low expression of cyclin A, showing a significant association with unfavorable prognosis in colon cancer. 18 It has been suggested that a decrease, rather than increase, in cyclin A in cells promotes tumorigenesis, and once the tumor has developed, high levels of cyclin A indicate the high proliferation rate, 2 which could explain this inconsistency of those studies. Only a few reports concerning cyclin A expression in gastric cancer have been made, but no correlation with survival was evident.…”

Section: Discussionmentioning

confidence: 74%

“…A value less than 5% was considered negative, and one equal to or greater than 5% was considered positive. 17,18 Cyclin A immunostaining was scored in a consensus manner without preliminary knowledge of clinical data (J.M. and S.N.).…”

Section: Scoringmentioning

confidence: 99%

Prognostic significance of cyclin A in gastric cancer

Mrena

Wiksten

Kokkola

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

High level of cyclin A promotes carcinogenesis, and overexpression of cyclin A has been associated with poor prognosis of cancer patients. We validated the prognostic role of cyclin A in gastric cancer and evaluated its correlation with expression of an mRNA stability factor HuR. From 342 consecutive histologically confirmed gastric cancer patients were obtained 325 representative tissue specimens for cyclin A and 316 for HuR immunohistochemistry. Specimens were stained by cyclin A and HuR specific monoclonal antibodies. Nuclear immunostaining detected in 5% of the tumor cells was considered the cut-off for cyclin A positivity. Positive HuR immunoreactivity was scored as nuclear or cytoplasmic. Associations between scores, clinicopathological factors and survival were calculated by the v 2 -test, Fisher's exact test, Kaplan-Meier test and Cox model. Cyclin A detected in the nuclei of cancer cells was positive in 55% (179 of 325) of the specimens; 40% (127 of 316) of the specimens had cytoplasmic and 88% (279 of 316) nuclear immunoreactivity of HuR. Cyclin A expression was an independent prognostic factor for poor survival. Cyclin A immunoreactivity was associated with old age, high stage, proximal location of the tumor, intestinal type, noncurative resection, advanced penetration depth and with nodal metastases but not distant metastases. Furthermore, cyclin A expression was associated with cytoplasmic HuR expression, whereas no association with nuclear HuR was evident. Cyclin A is an independent prognostic factor in gastric cancer, and one mechanism for its overexpression may depend on cytoplasmic localization of HuR. ' 2006 Wiley-Liss, Inc.Key words: cyclin A; HuR; gastric cancer; prognosis; survival Cyclin A belongs to the cyclin protein superfamily, and it can activate two different cyclin-dependent kinases, CDK1 and CDK2. The level of cyclin A accumulates progressively throughout the interphase and disappears rapidly at the end of mitosis. Currently, phosphorylated cyclin A-CDK complex is suggested to play an important role in the initiation of DNA replication in the S phase. The precise function of cyclin A in mitosis is unclear, but it may prevent other cyclins from degradation. Overexpression of cyclin A and dysregulation of CDK-cyclin complexes promote tumor cell growth, which can be facilitated by phosphorylation of oncoproteins and tumor suppressors. 1,2 In gastric cancer, cell-cycle regulators have been connected with poor prognosis. For example, overexpression of cyclin E, which also binds to CDK2 and controls the G1-S transition, has been associated with aggressive disease. 3,4 Furthermore, strongly positive cyclin E in the tumors of patients having surgery with intent to cure is a marker of poor prognosis, and concurrent expression of cyclin E and p53 is an independent prognostic factor. 5 However, there are also reports indicating that cyclin E expression does not correlate with clinicopathological parameters, 6 or is associated with good prognosis. 7 Overexpression of cyclin A correlates with po...

show abstract

“…Little is known about the regulation of the CAK complex though cyclin H [24,25]. Immunohistochemistry and real time quantitative polymerase chain reaction were used to determine cyclin expression and gene amplification in 219 tumors; the results indicated that cyclin H was overexpressed in all tumors [26][27][28]. These results mentioned above indicated that several biomarkers for cancer diagnosis can be found in a 2D-PAGE gel according to the approach describes hereto.…”

Section: Differential Protein Identificationmentioning

confidence: 79%

Biomarkers of liver-cancer discovered from the male patients crude serum without depletion of high abundance proteins

Luo¹,

Lin²,

Zeng³

et al. 2018

Cancer Rep Rev

View full text Add to dashboard Cite

High abundance proteins (HAP) were often removed from crude serum sample when finding biomarkers of diagnosing cancers, however, it will surely filtrate many potential biomarkers bound to HAP. In order to enable the detection of these potential biomarkers, saving the HAP will be of great significance for finding more biomarkers. Here, a serum proteomics technology was developed for finding biomarkers of liver-cancer from crude human serum without depletion of HAP. The crude human serum (CHS) was dispersed in a lysis buffer that has capacities for improving the protein resolution, and then separated with two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) for proteomic analysis. The differentially expressed proteins from Crude male serum (CMS) compared to crude serum of male patient with liver cancer (LCMPCS) were found and identified by a combined off-line approach of 2D-PAGE and matrix-assisted laser desorption/ ionization-time of flight mass spectrometry (MALDI-TOF). Approximately 800 protein spots on a 2D-PAGE gel were detected by Melanie 4 software from samples both CMS and LCMPCS in the present of the lysis buffer. Significantly different expression of 24 proteins were detected in the LCMPCS compared to that in the CMS. Among these proteins, fifty were found up-regulated and eleven were found down-regulated. Most of these differently regulated proteins were identified by PMF and database search. These differential expression proteins were reported participating in some key pathway or biology process in cancer cells, indicating that they may present a biomarkers profile and may be helpful for liver-cancer diagnosis.

show abstract

Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome

Cited by 66 publications

References 43 publications

Expression of cyclin E in stage III colorectal carcinoma

Expression of cyclin E in stage III colorectal carcinoma

Prognostic significance of cyclin A in gastric cancer

Biomarkers of liver-cancer discovered from the male patients crude serum without depletion of high abundance proteins

Contact Info

Product

Resources

About